Wall Street analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to post earnings of $0.31 per share for the current quarter, according to Zacks. Six analysts have made estimates for Medidata Solutions’ earnings, with estimates ranging from $0.25 to $0.38. Medidata Solutions posted earnings per share of $0.33 in the same quarter last year, which suggests a negative year-over-year growth rate of 6.1%. The firm is scheduled to report its next quarterly earnings results on Thursday, February 8th.
According to Zacks, analysts expect that Medidata Solutions will report full year earnings of $1.27 per share for the current year, with EPS estimates ranging from $1.21 to $1.34. For the next financial year, analysts expect that the firm will report earnings of $1.46 per share, with EPS estimates ranging from $1.31 to $1.61. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. The company had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share.
A number of research firms recently weighed in on MDSO. BidaskClub upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Tuesday. Dougherty & Co began coverage on shares of Medidata Solutions in a research note on Thursday, November 2nd. They set a “neutral” rating on the stock. Royal Bank of Canada restated a “hold” rating and set a $80.00 target price on shares of Medidata Solutions in a research note on Friday, October 27th. Deutsche Bank began coverage on shares of Medidata Solutions in a research note on Friday, December 8th. They set a “buy” rating and a $78.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $84.54.
Shares of Medidata Solutions (NASDAQ:MDSO) traded up $0.30 during trading hours on Friday, reaching $66.86. 584,347 shares of the company’s stock were exchanged, compared to its average volume of 330,994. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. The stock has a market capitalization of $3,891.16, a price-to-earnings ratio of 95.52, a PEG ratio of 3.45 and a beta of 1.69. Medidata Solutions has a one year low of $47.77 and a one year high of $85.92.
In other Medidata Solutions news, CFO Rouven Bergmann sold 2,000 shares of the stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $65.95, for a total value of $131,900.00. Following the transaction, the chief financial officer now directly owns 89,775 shares in the company, valued at $5,920,661.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Tarek Sherif sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. Insiders have sold 239,010 shares of company stock worth $16,437,036 over the last 90 days. Insiders own 5.80% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Frontier Capital Management Co. LLC increased its stake in Medidata Solutions by 12.0% in the fourth quarter. Frontier Capital Management Co. LLC now owns 54,912 shares of the company’s stock valued at $3,480,000 after purchasing an additional 5,863 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Medidata Solutions by 6.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 347,388 shares of the company’s stock valued at $22,014,000 after purchasing an additional 20,438 shares during the last quarter. Summit Creek Advisors LLC purchased a new position in Medidata Solutions in the fourth quarter valued at approximately $5,137,000. KAMES CAPITAL plc increased its stake in Medidata Solutions by 54.6% in the fourth quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock valued at $1,617,000 after purchasing an additional 9,012 shares during the last quarter. Finally, California Public Employees Retirement System increased its stake in Medidata Solutions by 1.2% in the third quarter. California Public Employees Retirement System now owns 104,076 shares of the company’s stock valued at $8,124,000 after purchasing an additional 1,276 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “$0.31 Earnings Per Share Expected for Medidata Solutions Inc (MDSO) This Quarter” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/20/0-31-earnings-per-share-expected-for-medidata-solutions-inc-mdso-this-quarter.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Get a free copy of the Zacks research report on Medidata Solutions (MDSO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.